Abstract:

Transfusion, as it could be a life-saving therapy itself, was also found to cause complications that could put life at risk. Transfusion-related graft versus host disease (Ti-GVHH) is a fatal complication that rarely develops after blood transfusions. TI-GVHH was first defined as a mortal disease in the 1960s by Nispet and Heskop, which developed with the administration of lymphocytes that preserve their immune properties to an individual with immune deficiency. Though TI-GVH is most often associated with erythrosite transfusion, it can develop with thrombocytes, granulocytes and unfried plasma transfusions. Its basic mechanism develops depending on the function of distinguishing the self and the non-self, which is the primary function of the immune system. This risk should be accompanied by either an immunosuppressed recipient or a partial HLA similarity to the transfused blood. It is known that both primary and secondary immune failure develops with TI-GVH. The partial HLA similarity represents the chismic similarity of the recipient and the donor’s HLA genes in transfusion. The most common symptoms are skin outbreak, fever, hepatitis, pansitopenia, diarrhea, bone marrow hypoplasia/aplasia. The diagnosis is severe and begins first with suspicion.The treatment, as it is noted, is a difficult disease. Therefore, the replacement indication must be placed correctly. If replacement is planned, blood product radiation should be provided in dangerous patients.Other preventive methods are pathogen inactivation, ice-solving and leukocyte filtration. The exact treatment is alloogenic bone marrow transplant. It can not be used in immunosuppressant agents that are not suitable for transplant or in the time of transplant.

Keywords: